Title
Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers
Author
Pieterman, E.J.
Princen, H.M.G.
Jarke, A.
Nilsson, R.
Cavallin, A.
Bergenholm, L.
Henricsson, M.
Gopaul, V.S.
Agrawal, R.
Nissen, S.E.
Hurt-Camejo, E.
Publication year
2021
Abstract
We investigated the effects of chronic oral administration of mineral oil, versus corn oil as control, on intestinal permeability, inflammatory markers, and plasma lipids in APOE*3-Leiden.CETP mice. Mice received mineral oil or corn oil 15 or 30 μL/mouse/day for 16 weeks (15 mice/group). Intestinal permeability was increased with mineral versus corn oil 30 µL/day, shown by increased mean plasma FITC-dextran concentrations 2 h post-administration (11 weeks: 1.5 versus 1.1 μg/ml, p = 0.02; 15 weeks: 1.7 versus 1.3 μg/ml, p = 0.08). Mean plasma lipopolysaccharide-binding protein levels were raised with mineral versus corn oil 30 µL/day (12 weeks: 5.8 versus 4.4 μg/ml, p = 0.03; 16 weeks: 5.8 versus 4.5 μg/ml, p = 0.09), indicating increased intestinal bacterial endotoxin absorption and potential pro-inflammatory effects. Plasma cholesterol and triglyceride concentrations were decreased with mineral oil, without affecting liver lipids among treated groups. Fecal neutral sterol measurements indicated increased fecal cholesterol excretion with mineral oil 30 µL/day (+16%; p = 0.04). Chronic oral administration of mineral oil in APOE*3-Leiden.CETP mice increased intestinal permeability, with potential pro-inflammatory effects, and decreased plasma cholesterol and triglyceride levels. Our findings may raise concerns about the use of mineral oil as a placebo in clinical studies.
Subject
APOE*3-Leiden.CETP mice
Cholesterol
Fatty acids
Intestinal permeability
Triglycerides
Mineral
Oil
Corn
Biomedical Innovation
Healthy Living
Life
MHR - Metabolic Health Research
ELSS - Earth, Life and Social Sciences
To reference this document use:
http://resolver.tudelft.nl/uuid:6fb5e34c-0006-40e0-adb8-756de56cc2d2
DOI
https://doi.org/10.3389/fphar.2021.681455
TNO identifier
958856
Source
Frontiers in Pharmacology, 12 (12)
Document type
article